Lack of bcl-2 Persistence: An Independent Prognostic Indicator of Poor Prognosis in Endometrial Carcinoma

AbstractKinesins play important roles in the progression and development of cancer. Kinesin family member C1 (KIFC1), a minus end-directed motor protein, is a novel Kinesin involved in the clustering of excess centrosomes found in cancer cells. Recently KIFC1 has shown to play a role in the progression of many different cancers, however, the involvement of KIFC1 in the progression of prostate cancer (PCa) is still not well understood. This study investigated the expression and clinical significance of KIFC1 in PCa by utilizing multiple publicly available datasets to analyze KIFC1 expression in patient samples. High KIFC1 expression was found to be associated with high Gleason score, high tumor stage, metastatic lesions, high ploidy levels, and lower recurrence-free survival. These results reveal that high KIFC1 levels are associated with a poor prognosis for PCa patients and could act as a prognostic indicator for PCa patients as well.

Download Full-text

Overexpression of HER-2/neu in endometrial carcinoma is associated with poor prognosis

Gynecologic Oncology ◽

10.1016/0090-8258(91)90116-m ◽

1991 ◽

Vol 40 (2) ◽

pp. 169

Author(s):

A. Berchuck ◽

G. Rodriguez ◽

R.B. Kinney ◽

J.T. Soper ◽

D.L. Clarke-Pearson ◽

...

Keyword(s):

Endometrial Carcinoma ◽

Poor Prognosis ◽

Her 2

Download Full-text

Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer

Cellular Physiology and Biochemistry ◽

10.1159/000494467 ◽

2018 ◽

Vol 50 (3) ◽

pp. 810-822 ◽

Cited By ~ 16

Author(s):

Nan Sheng ◽

Yun-Zhao Xu ◽

Qing-Hua Xi ◽

Hai-Yan Jiang ◽

Chen-Yi Wang ◽

...

Keyword(s):

Ovarian Cancer ◽

Cell Proliferation ◽

Cancer Cell ◽

Poor Prognosis ◽

Ovarian Cancer Cell ◽

Expression Profiles ◽

Annexin V ◽

Prognostic Indicator ◽

Luciferase Reporter ◽

Migration And Invasion

Background/Aims: This study aimed to investigate the expression and prognostic value of kinesin family member 2A (KIF2A) and the suppression effects of microRNA-206 (miR-206) on KIF2A in ovarian cancer. Methods: Ovarian cancer tissues from patients and ovarian cancer cell lines (A2780 and SKOV3) were used in this study. miR-206 mimics and control were transiently transfected into cells. RT-qPCR was performed to detect KIF2A mRNA and miR-206 expression levels, Western blot was performed to detect KIF2A protein levels, Dual-Luciferase Reporter Assay was used to examine the inhibition effects of miR-206 on KIF2A mRNA, immunohistochemical staining was used to examine the expression of KIF2A in tissue sections. CCK-8, transwell and Annexin-V-FITC/Propidium Iodide staining with flow cytometry were used to detect the cell proliferation, migration/invasion, and apoptosis respectively. Results: Our study explored the expression profiles of KIF2A and miR-206 in the patients with ovarian cancer. We found that overexpression of KIF2A was associated with a poor prognosis in ovarian cancer. We also found that KIF2A mRNA contains two target sites for miR-206 binding and confirmed that miR-206 directly suppresses KIF2A; inhibits ovarian cancer cell proliferation, migration, and invasion; and induces apoptosis. Conclusion: The results suggest KIF2A could serve a valuable prognostic indicator in ovarian cancer and provide a rationale for treatment of ovarian cancer by targeting KIF2A via miR-206.

Download Full-text

Synovial Sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment

Journal of Clinical Oncology ◽

10.1200/jco.2000.18.22.3794 ◽

2000 ◽

Vol 18 (22) ◽

pp. 3794-3803 ◽

Cited By ~ 227

Author(s):

Andrew J. Spillane ◽

Roger A’Hern ◽

Ian R. Judson ◽

Cyril Fisher ◽

J. Meirion Thomas

Keyword(s):

Survival Rate ◽

Synovial Sarcoma ◽

Poor Prognosis ◽

Objective Response ◽

Staging System ◽

Complete Response ◽

Prognostic Indicator ◽

Pulmonary Metastasectomy ◽

Prognostic Assessment ◽

Clinicopathologic Staging

PURPOSE: Synovial sarcoma (SS) is a common soft tissue sarcoma (STS) with a propensity for young adults and notable sensitivity to chemotherapy (CT). This study provides a current clinicopathologic, staging, and prognostic assessment for SS. The problems with the current American Joint Committee for Cancer (AJCC) Staging System in relation to SS are discussed. METHODS: Review of a prospective database supplemented by retrospective data. RESULTS: One hundred fifty patients were assessed; median age was 30 years and median follow-up was 52 months. Overall actuarial 5-year survival rate was 57%. Size trend, but not a cutoff of less than 5 cm versus ≥ 5 cm, was a prognostic indicator (P < .001). The current AJCC/International Union Against Cancer Staging System differentiated prognosis less well than the recently proposed Royal Marsden Hospital Staging System. Age greater than 20 years at diagnosis implied worse prognosis. A local recurrence event was associated with a worse survival (P < .001). Therapeutic CT was administered to 55 patients. Eleven of 19 patients had an objective response to a combination of ifosfamide and doxorubicin. Four cases had complete response after CT. Twenty-one patients had pulmonary metastasectomy, with an actuarial 5-year survival rate of 23%. CONCLUSION: SS tends to affect young people. In this subtype of STS, size trend is the most significant influence on stage and hence survival; however, smaller SSs have an unexpectedly poor prognosis. Adequate local control may affect survival. SS is often chemosensitive, and given its poor prognosis, multicenter trials of adjuvant therapy are warranted.

Download Full-text

Integrated analysis of immune-related genes in endometrial carcinoma

Cancer Cell International ◽

10.1186/s12935-020-01572-6 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Yiru Wang ◽

Yunduo Liu ◽

Yue Guan ◽

Hao Li ◽

Yuan Liu ◽

...

Keyword(s):

Transcription Factors ◽

Endometrial Carcinoma ◽

Roc Analysis ◽

Prognostic Indicator ◽

Integrated Analysis ◽

High Morbidity ◽

Qrt Pcr ◽

Kaplan Meier ◽

Potential Biomarker ◽

Immune Related Genes

Abstract Background Exploring novel and sensitive targets is urgent due to the high morbidity of endometrial cancer (EC). The purpose of our study was to explore the transcription factors and immune-related genes in EC and further identify immune-based lncRNA signature as biomarker for predicting survival prognosis. Methods Transcription factors, aberrantly expressed immune-related genes and immune-related lncRNAs were explored through bioinformatics analysis. Cox regression and the least absolute shrinkage and selection operator (LASSO) analysis were conducted to identify the immune and overall survival (OS) related lncRNAs. The accuracy of model was evaluated by Kaplan–Meier method and receiver operating characteristic (ROC) analysis, and the independent prognostic indicator was identified with Cox analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) were conducted to detect the accuracy of our results. Results A network of 29 transcription factors and 17 immune-related genes was constructed. Furthermore, four immune-prognosis-related lncRNAs were screened out. Kaplan–Meier survival analysis and time-dependent ROC analysis revealed a satisfactory predictive potential of the 4-lncRNA model. Consistency was achieved among the results from the training set, testing set and entire cohort. The distributed patterns between the high- and low-risk groups could be distinguished in principal component analysis. Comparisons of the risk score and clinical factors confirmed the four-lncRNA-based signature as an independent prognostic indicator. Last, the reliability of the results was verified by qRT-PCR in 29 cases of endometrial carcinoma and in cells. Conclusions Overall, our study constructed a network of transcription factors and immune-related genes and explored a four immune-related lncRNA signature that could serve as a novel potential biomarker of EC.

Download Full-text

Papillary Serous and Clear Cell Type Lead to Poor Prognosis of Endometrial Carcinoma in Black Women

Gynecologic Oncology ◽

10.1006/gyno.1997.4617 ◽

1997 ◽

Vol 65 (2) ◽

pp. 206-212 ◽

Cited By ~ 82

Author(s):

Roland P. Matthews ◽

Juana Hutchinson-Colas ◽

Mitchell Maiman ◽

Rachel G. Fruchter ◽

E.Jason Gates ◽

...

Keyword(s):

Black Women ◽

Endometrial Carcinoma ◽

Poor Prognosis ◽

Clear Cell ◽

Cell Type ◽

Clear Cell Type

Download Full-text

Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma

British Journal of Cancer ◽

10.1038/bjc.1996.401 ◽

1996 ◽

Vol 74 (4) ◽

pp. 562-567 ◽

Cited By ~ 61

Author(s):

R Soong ◽

S Knowles ◽

KE Williams ◽

IG Hammond ◽

SJ Wysocki ◽

...

Keyword(s):

Endometrial Carcinoma ◽

P53 Protein ◽

Prognostic Indicator

Download Full-text

Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM).

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.8024 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 8024-8024

Author(s):

Chutima Kunacheewa ◽

Krina K. Patel ◽

Hans Chulhee Lee ◽

Sheeba K. Thomas ◽

Behrang Amini ◽

...

Keyword(s):

Poor Prognosis ◽

Residual Disease ◽

Response Assessment ◽

Study Groups ◽

Prognostic Indicator ◽

Initial Therapy ◽

Rank Test ◽

New Treatments ◽

The Impact

8024 Background: MRD is a standard measurement for response assessment in MM. Despite new treatments, HRM patients continue to have poor prognosis. We evaluated the impact of MRD- in high vs standard (SRM) risk patients. Methods: We retrospectively evaluated all consecutive MM/plasma cell leukemia patients who had routine MRD testing by 1-tube 8-color advanced flow cytometry with 2,000,000 events and sensitivity level 10-5 at our center from 2015-2018 after initial therapy. Kaplan-Meier and log-rank test were used to assess survival estimates and differences between study groups. Results: 136 patients with MRD testing after initial therapy/autologous transplant (ASCT) were identified. Patient and disease characteristics are included in Table. At a median follow-up of 14 months (1-36), PFS and OS were significantly worse in HRM vs SRM. During the study period, 50% of HRM had progressed (relapse and/or death) vs 20% in SRM (p=0.0006). No patients with SRM died, but 4 (14%) in the HRM group did (p=0.0007). Regardless of MRD status, HRM patients had statistically significant worse PFS than SRM; at median f/u 10% SRM MRD-; 20% SRM MRD+; 40%HRM MRD-; 45% HRM MRD+ had either relapsed or died (p=0.0041). MRD status did not impact OS in either group (p=0.0914), however longer follow up is needed to assess survival. Conclusions: Genetic abnormalities (FISH/GEP) remain a powerful prognostic indicator for myeloma regardless of MRD status. For newly diagnosed myeloma patients treated with novel triple initial therapy and frontline ASCT, achieving MRD negative status didn’t mitigate the poor prognosis outcomes of HRM. [Table: see text]

Download Full-text